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Fig. 1. Kaplan-Meier analysis showing that CF patients with hemoglobin≤ 12.9 g/dl
were more likely than those with higher values to receive to antibiotics.Hemoglobin ≤ 12.9 g/dl predicts risk of antibiotic
treatment in cystic fibrosis
I read with interest the letter by Kathiresan et al. [1] reporting
their observations of statistically-significant increases in hemo-
globin concentration during 156 consecutive admissions of cystic
fibrosis (CF) patients for the treatment of infective exacerbation
with parenteral antibiotics. These authors classified admissions
based on the presence (n = 51) or absence (n = 105) of anemia
prior to treatment. They found that hemoglobin improved by
0.7 g/dl (p b 0.001) and 0.2 g/dl (p = 0.047) when anemia was
present and not present, respectively, at admission. Hemoglobin
responses in both groups were unrelated to prior use of an oral
iron supplement. They concluded that intravenous antibiotics
improved hemoglobin during exacerbation by increasing iron
availability, which in turn reflected lower activity of interleukin-6
(IL-6) and hepcidin-25. Indeed, IL-6 stimulates hepatic produc-
tion of hepcidin-25, a hormone that induces hypoferremia by
restricting duodenal iron absorption [2] and causing mononuclear
cells to retain iron [3].
I believe that in order to accurately interpret the findings of
Kathiresan et al. [1], the authors should specify the hemoglobin
cutoffs used to distinguish anemia and clarify whether patients
with repeated exacerbations were included in the analysis. In a
cross-sectional study [4], our group has shown that 14 adult CF
patients with median plasma iron and hemoglobin concentrations
of 3.6 μmol/l and 11.3 g/dl, respectively, had significantly worse
lung function and lower body mass index than 25 CF patients of
similar age with respective median plasma iron and hemoglobin
levels of 9.0 μmol/l and 13.5 g/dl. Based on these observations,
we concluded that anemia and hypoferremia are emblematic of
disease severity.
It is reasonable to speculate that severely anemic and
hypoferremic CF patients are not only more likely to have
exacerbations but also more likely to respond to antibiotics with an
increase in hemoglobin. If such patients were repeatedly admitted,
and hence, constituted a high percentage of consecutive admissions
analyzed by Kathiresan et al. [1], their findings may apply to
specific patients. I cannot find published data which relates
hospitalization risk to anemia severity. In a retrospective analysis
of risk factors for oral or intravenous antibiotic treatment in 55
unique adults treated at our CF center, we determined that a1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.06.007one-time hemoglobin measurement ≤12.9 g/dl was associated
with higher risk of subsequent treatment (HR = 1.63, 95% CI
0.94–2.86, p = 0.049) (Fig. 1). It would be interesting to know if
patients who were defined as anemic and considered more than
once in their series had hemoglobin levels b12.9 g/dl at the time
of admission.
In our recent description of iron homeostasis during CF
exacerbation [5], we reported that IV antibiotics increased median
serum iron level by 2.42 μmol/l and reduced median serum
IL-6 and hepcidin-25 concentrations by 12.1 pg/ml and 37.5,
respectively, among 12 unique adults who were hospitalized for
exacerbation (p b 0.05 for all comparisons). Thus, we confirmed
the aforementioned postulate of Kathiresan et al. [1], but we did
not detect a statistically-significant difference in hemoglobin
concentration after 12 days of treatment. Aggressive phlebotomy
did not explain this finding. It remains possible that the increase
in serum iron was insufficient for erythropoiesis, that erythropoi-
esis was still blunted by inflammation, or that the equivocal
hemoglobin difference represented type II error. The critical
implications of our data and those of Kathiresan et al. [1] are that
antibiotics dramatically influence circulatory biomarkers of iron
status and may have a positive effect on hemoglobin concentra-
tion in this patient population.by Elsevier B.V. All rights reserved.
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